Calidi to Unveil CLD-401 IL-15 Virotherapy Data, Aims for IND Filing by Year-End
CLDI•Dr. Antonio Santidrian will present new preclinical data on Calidi’s RedTail platform and CLD-401 virotherapy, engineered to deliver IL-15 superagonist directly into tumors, at the ASGCT conference in Boston. The company plans to file an IND for CLD-401 by end-2026 and highlighted RedTail’s CLD-501 T-cell engager program in separate data.
1. ASGCT Conference Presentation
Calidi’s Chief Scientific Officer, Dr. Antonio F. Santidrian, will deliver a featured speaker session at the ASGCT annual meeting in Boston, detailing the engineering and therapeutic promise of the RedTail platform and its lead asset, CLD-401. The presentation will focus on systemic delivery of virotherapy to metastatic tumor sites and immune modulation within the tumor microenvironment.
2. RedTail Platform and CLD-401 Details
The proprietary RedTail platform is an enveloped oncolytic virus designed for systemic administration, selectively targeting tumors and expressing high levels of IL-15 superagonist within the tumor microenvironment. Preclinical results show robust T- and NK-cell recruitment and activation, and the company intends to file an IND for CLD-401 by the end of 2026.
3. CLD-501 Program and Strategic Partnerships
Beyond CLD-401, Calidi showcased data on CLD-501, a tumor-targeted T-cell engager expressed in situ via RedTail, at a separate oncology conference. The company is actively pursuing strategic partnerships to accelerate clinical development and expand the platform’s application across multiple solid tumor indications.
